Join this week's Happy Hour for the scoop on drugs, flicks and Eliot Spitzer.

With biotech stocks on the ropes, Happy Hour co-hosts Chris Edmonds and Eric Gillin check in with

TheStreet.com

's biotech ace, Adam Feuerstein, to find out about potential new drugs in the pipelines and any bargain stocks in the downtrodden sector. Just back from the American Society of Clinical Oncology meeting, Adam offers insight on

ImClone

(IMCL)

,

Protein Design Labs

(PDLI) - Get Report

and

AstraZeneca

(AZN) - Get Report

.

Plus, the Markets Roundtable takes a close look at

Merrill Lynch's

(MER)

settlement with New York Attorney General Eliot Spitzer. Join the discussion with Ted Bridges, chief investment strategist at Bridges Investment Counsel, and

TheStreet.com's

executive editor, Mike Anderson.

And, with

Spider-Man

and the new

Star Wars

flick setting a high bar for other summer blockbusters, Chris and Eric chat with David Miller, analyst at Sanders Morris Harris, to find out which companies are poised to benefit from success at the box office.

Join the show at 5 p.m. EDT Thursday by clicking on the Happy Hour tile at the top of the site.

David Morrow is editor-in-chief of TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, though he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He welcomes your feedback and invites you to send it to

David Morrow.